Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Childhood cerebral adrenoleukodystrophy (CCER), adrenomyeloneuropathy (AMN) and AMN with cerebral demyelination (AMN-C) are the main phenotypic variants of X-linked adrenoleukodystrophy (ALD). It is caused by mutations in the ABCD1 gene encoding a half-size peroxisomal transporter that has to dimerize to become functional. The biochemical hallmark of ALD is the accumulation of very-long-chain fatty acids (VLCFA) in plasma and tissues. However, there is no correlation between the ALD phenotype and the ABCD1 gene mutations or the accumulation of VLCFA in plasma and fibroblast from ALD patients. The absence of genotype-phenotype correlation suggests the existence of modifier genes. To elucidate the mechanisms underlying the phenotypic variability of ALD, we studied the expression of ABCD1, three other peroxisomal transporter genes of the same family (ABCD2, ABCD3 and ABCD4) and two VLCFA synthetase genes (VLCS and BG1) involved in VLCFA metabolism, as well as the VLCFA concentrations in the normal white matter (WM) from ALD patients with CCER, AMN-C and AMN phenotypes. This study shows that: (1) ABCD1 gene mutations leading to truncated ALD protein are unlikely to cause variation in the ALD phenotype; (2) accumulation of saturated VLCFA in normal-appearing WM correlates with ALD phenotype and (3) expression of the ABCD4 and BG1, but not of the ABCD2, ABCD3 and VLCS genes, tends to be correlated with the severity of the disease, acting early in the pathogenesis of ALD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the intact brain white matter of cALD patients, C26:0 is 1.5-fold higher than in “pure” AMN [155].”
From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [155]
In the citing paper
“There is some evidence that the amount of VLCFAs may be directly related to the risk of developing inflammatory demyelination.115”
From The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis (2015) · cites this paper as [115]
In the citing paper
“While for ABCD2, ABCD3, and ACSVL1 no significant differences in mRNA expression levels were found in brain tissues when comparing CALD and AMN”
From The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis (2015) · cites this paper as [115]
In the citing paper
“an altered expression of ACSBG1 and ABCD4 mRNA was observed in normal appearing white matter of CALD patients.115”
From The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis (2015) · cites this paper as [115]
In the citing paper
“In 2005, Asheuer and coworkers demonstrated that brain VLCFA levels in normal appearing white matter correlate with the clinical phenotype [34].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [34]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189 · cited 1×
“Total lipids were extracted using 2:1 (vol/vol) chloroform/methanol and the Folch method (63).”
MethodLock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 2×
“This study shows that: (1) ABCD1 gene mutations leading to truncated ALD protein are unlikely to cause variation in the ALD phenotype; (2) accumulation of saturated VLCFA in normal-appearing WM correlates with ALD phenotype and (3) expression of the ABCD4 and BG1, but not of the ABCD2, ABCD3 and VLCS genes, tends to b…”
BackgroundSelf-citationCholesterol, lipid rafts, and disease
Simons, K., & Ehehalt, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16390 · Cited by 989 · cited 1×
“The formation of VLCFA-containing ChE could not only trap the VLCFA leading to increased levels, but also impair cellular processes at the plasma membrane by modifying the cholesterol/ChE ratio (51).”
BackgroundRecommendations for a nomenclature system for human gene mutations
Antonarakis, S. E., & Nomenclature Working Group (1998) · Human Mutation · doi:10.1002/(sici)1098-1004(1998)11:1<1::aid-humu1>3.0.co;2-o · Cited by 943
Cholesterol, lipid rafts, and disease
Simons, K., & Ehehalt, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216390 · Cited by 916
Imai, Y., Ibata, I., Ito, D., Ohsawa, K., & Kohsaka, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1112 · Cited by 872 · cited 2×
“Rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1) antibody (dilution 1:400, Imai, Japan (60)) was used to detect microglial activation.”
MethodMoser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Nonsense-mediated decay approaches the clinic
Holbrook, J. A., Neu-Yilik, G., Hentze, M. W., & Kulozik, A. E. (2004) · Nature Genetics · doi:10.1038/ng1403 · Cited by 596 · cited 2×
“The protective effects of the NMD pathway against the production of faulty proteins have been suggested or demonstrated in several other hereditary disorders, including b-thalassemia (40).”
BackgroundElongation of long-chain fatty acids
Leonard, A. E., Pereira, S. L., Sprecher, H., & Huang, Y.-S. (2004) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00040-7 · Cited by 584 · cited 2×
“The reduction of mono-unsaturated VLCFA observed in the WM from CCER and AMN-C patients may reflect substrate competition between saturated and mono-unsaturarted long chain fatty acids for the two elongases (ELOVL1 and ELOVL3) that display chain-length specificity toward VLCFA (36).”
Background
Research works printed but not linked: 4
- Steinberg, S.J., Kemp, S., Braiterman, L.T. and Watkins, P.A. (1999) Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy. Ann. Neurol., 46, 409–412. · doi:10.1002/1531-8249(199909)46:3<409::aid-ana18>3.0.co;2-9
- den Dunnen, J.T. and Antonarakis, S.E. (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat., 15, 7–12. · DOI · Paper page
- Silva-Zolezzi, I., Hebron, K., Mihalik, S., Thomas, G., Valle, D. and Jimenez-Sanchez, G. (2003) Abcd3−/− mice have a non-shivering thermogenesis defect related to a disturbance in fasting fuel homeostasis. Proceedings of the 53rd Annual Meeting of The American Society of Human Genetics. The American Society of Human Genetics, Los Angeles, California, Suppl. to Vol. 73, p. 199.
- Moser, A.B., Kreiter, N., Bezman, L., Lu, S., Raymond, G.V., Naidu, S. and Moser, H.W. (1999) Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann. Neurol., 45, 100–110. · doi:10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u
Cited by
Chemotherapy-induced resistance by ATP-binding cassette transporter genes
GILLET, J., EFFERTH, T., & REMACLE, J. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.05.002 · Cited by 337
X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283
“However, positive association studies with variants in genes involved in methionine metabolism [77,78], and SOD2 [79], or altered gene expression of Bubblegum (a member of the VLCFacyl-CoA synthetase family) [34], and ABCD4 (PMP69/P70R, another half ABC-transporter with high homology to ALDP) [34], might indicate thei…”
Self-citationPathophysiology of X-linked adrenoleukodystrophy
Berger, J., Forss-Petter, S., & Eichler, F. S. (2014) · Biochimie · doi:10.1016/j.biochi.2013.11.023 · Cited by 238
“Although VLCFA levels in blood or cultured fibroblasts are indistinguishable in X-ALD patients with different clinical phenotypes, the amounts of VLCFA were found to be higher in normal appearing white matter of CALD patients compared with AMN patients [65].”
ResultEarly oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214
“Also, there is no correlation between the ALD phenotype and the accumulation of VLCFA in plasma and fibroblasts from ALD patients, although a recent study suggests a link between the levels of VLCFA in white matter and disease severity (7).”
BackgroundTurk, B. R., Theda, C., Fatemi, A., & Moser, A. B. (2020) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10003 · Cited by 210
“However, the amounts of VLCFA levels in normal appearing white matter were found to be higher in CALD compared with the levels in pure AMN (Asheuer et al., 2005).”
ResultSelf-citationX-linked adrenoleukodystrophy: Clinical, biochemical and pathogenetic aspects
Berger, J., & Gärtner, J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.07.010 · Cited by 199
“Only recently, it was observed that the mRNA level of Bubblegum, another newly identified member of the very long-chain acyl-CoA synthetase family [57 – 62], is decreased in normal appearing white matter of X-ALD brain in correlation with the severity of the disease [63].”
BackgroundX-Linked Adrenoleukodystrophy: Pathogenesis and Treatment
Engelen, M., Kemp, S., & Poll-The, B.-T. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0486-0 · Cited by 187
Peroxisomal ABC transporters: Structure, function and role in disease
Morita, M., & Imanaka, T. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.009 · Cited by 183
“Asheuer et al. found that increase of C26:0 in normal appearing white matter in child cerebral ALD (CCALD) was higher than adrenomyeloneuropathy (AMN) [68].”
BackgroundInfluentialThe role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000061 · Cited by 170
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundMarquez, B., & Van Bambeke, F. (2011) · Current Drug Targets · doi:10.2174/138945011795378504 · Cited by 165
Berger, J., Wiesinger, C., & Eichler, F. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s49590 · Cited by 140
General aspects and neuropathology of X-linked adrenoleukodystrophy
Ferrer, I., Aubourg, P., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00390.x · Cited by 139
“Different clinical phenotypes have been reported in monozygotic twins (156), suggesting that genetic, epigenetic, environmental and stochastic factors are probably contributory to the development and course of the disease (1, 55, 76, 130).”
BackgroundSelf-citationBiochemical aspects of X-linked adrenoleukodystrophy
Kemp, S., & Wanders, R. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00391.x · Cited by 116
“More importantly, myelin from CCALD patients contains higher VLCFA levels than myelin from AMN patients (2).”
BackgroundInduced pluripotent stem cell models from X-linked adrenoleukodystrophy patients
Jang, J., Kang, H., Kim, H., Kim, J. Y., Huh, Y. J., Kim, D., Yoo, J., Lee, J., Lim, B., Lee, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22486 · Cited by 109
“On the contrary, recent studies with postmortem brain reported that accumulation of VLCFA in the white matter correlates with disease phenotype and severity.(15,16) However, unfortunately, VLCFA levels of oligodendrocytes cannot be readily measured from living X-ALD patients.”
ResultFerrer, I., Kapfhammer, J. P., Hindelang, C., Kemp, S., Troffer-Charlier, N., Broccoli, V., Callyzot, N., Mooyer, P., Selhorst, J., Vreken, P., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi384 · Cited by 106
“While this article was in preparation, a direct correlation between accumulation of saturated VLCFAs in brain white matter and disease severity in human X-ALD patients has been reported, shedding some light into the issue (47).”
BackgroundValproic acid induces antioxidant effects in X-linked adrenoleukodystrophy
Fourcade, S., Ruiz, M., Guilera, C., Hahnen, E., Brichta, L., Naudi, A., Portero-Otín, M., Dacremont, G., Cartier, N., Wanders, R., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq082 · Cited by 100
“Less information is available on ABCD4, except for the finding that ABCD4 expression levels in the brain of X-ALD patients are inversely correlated with phenotype severity (33).”
BackgroundSelf-citationCurrent and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy
Berger, J., Pujol, A., Aubourg, P., & Forss‐Petter, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00393.x · Cited by 90
“In good agreement with this hypothesis, Asheuer et al (3) reported higher C26:0 levels in normal appearing white matter of patients with the childhood cerebral phenotype than in those with AMN.”
ResultSelf-citationMoser, H. W., Moser, A. B., Hollandsworth, K., Brereton, N. H., & Raymond, G. V. (2007) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-0041-4 · Cited by 93
“Initially, there had been a great deal of concern about the safety of LO because high erucic acid oils had been found to produce a cardiac lipidosis in rodents ( Abdellatif 1972 ), but subsequent studies showed that this was not a significant issue in primates (Sauer and Kramer 1983).”
BackgroundSelf-citationWhite, K., Yang, P., Li, L., Farshori, A., Medina, A. E., & Zielke, H. R. (2018) · Biopreservation and Biobanking · doi:10.1089/bio.2017.0099 · Cited by 88
Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy
Schlüter, A., Espinosa, L., Fourcade, S., Galino, J., López, E., Ilieva, E., Morató, L., Asheuer, M., Cook, T., McLaren, A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr536 · Cited by 72
“Brain tissue sections were processed when two to three adjacent sections showed no sign of demyelination with LFB staining and no perivascular cuffs of lymphocytes using hematoxylin and eosin staining (6,15).”
BackgroundMethodSelf-citationUptake and metabolism of plasma-derived erucic acid by rat brain
Golovko, M. Y., & Murphy, E. J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600029-jlr200 · Cited by 70
Peroxisomes, myelination, and axonal integrity in the CNS
Baes, M., & Aubourg, P. (2009) · The Neuroscientist · doi:10.1177/1073858409336297 · Cited by 65
Self-citationRaas, Q., Gondcaille, C., Hamon, Y., Leoni, V., Caccia, C., Ménétrier, F., Lizard, G., Trompier, D., & Savary, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.02.006 · Cited by 53
Cappa, M., Bizzarri, C., Petroni, A., Carta, G., Cordeddu, L., Valeriani, M., Vollono, C., De Pasquale, L., Blasevich, M., & Banni, S. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9432-3 · Cited by 49
“Furthermore, a VLCFA acyl-CoA synthetase, has been found reduced in normal white matter from ALD patients and it has been associated with the early pathogenesis and severity of disease progression (Asheuer et al. 2005).”
BackgroundC26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man
van de Beek, M.-C., Dijkstra, I. M. E., van Lenthe, H., Ofman, R., Goldhaber-Pasillas, D., Schauer, N., Schackmann, M., Engelen-Lee, J.-Y., Vaz, F. M., Kulik, W., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154597 · Cited by 48
“However, biochemical analysis of normal-appearing grey and white matter that was dissected from frontal, parietal or occipital lobes from 17 ALD patients and 19 age-matched controls revealed a correlation between VLCFA levels and clinical phenotype [20].”
BackgroundNakayama, M., Sato, H., Okuda, T., Fujisawa, N., Kono, N., Arai, H., Suzuki, E., Umeda, M., Ishikawa, H., & Matsuno, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022984 · Cited by 53
“In adrenoleukodystrophy (ALD) patients, VLCFA levels in the white matter of the brain correlate with phenotypic severity, so the abnormal accumulation of VLCFAs is thought to be the cause of the neuronal damage associated with ALD [43].”
BackgroundLipid-induced endoplasmic reticulum stress in X-linked adrenoleukodystrophy
van de Beek, M.-C., Ofman, R., Dijkstra, I. M. E., Wijburg, F. A., Engelen, M., Wanders, R. J. A., & Kemp, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.003 · Cited by 51
Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy
Jaspers, Y. R. J., Yska, H. A. F., Bergner, C. G., Dijkstra, I. M. E., Huffnagel, I. C., Voermans, M. M. C., Wever, E. J. M., Salomons, G. S., Vaz, F. M., Jongejan, A., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00605-9 · Cited by 50
“Forexample, theaccumulationofsaturatedVLCFAinthenormal-appearingwhite matterofpatientswithcerebralALDishigherthaninindividualswithout cerebralinvolvement 58 .”
BackgroundX-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype
Maier, E. M., Mayerhofer, P. U., Asheuer, M., Köhler, W., Rothe, M., Muntau, A. C., Roscher, A. A., Holzinger, A., Aubourg, P., & Berger, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.092 · Cited by 34
“However, in a recent study it was demonstrated that the expression levels of ABCD2 in the normal-appearing white matter of brains derived from patients displaying different X-ALD phenotypes were similar and did not differ significantly from the levels observed in age-matched controls [25].”
BackgroundResultSelf-citationSingh, J., Khan, M., & Singh, I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m017491 · Cited by 37
Epigenomic signature of adrenoleukodystrophy predicts compromised oligodendrocyte differentiation
Schlüter, A., Sandoval, J., Fourcade, S., Díaz‐Lagares, A., Ruiz, M., Casaccia, P., Esteller, M., & Pujol, A. (2018) · Brain Pathology · doi:10.1111/bpa.12595 · Cited by 35
“Although disease severity may correlate with increased VLCFA content in the white matter (4), it remains to be determined whether excess VLCFAs may trigger cerebral inflammation and demyelination.”
BackgroundHabekost, C. T., Schestatsky, P., Torres, V. F., de Coelho, D. M., Vargas, C. R., Torrez, V., Oses, J. P., Portela, L. V., Pereira, F. D. S., Matte, U., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-6 · Cited by 35
“Although brain VLCFA levels correlated with CALD in hemizygotes [9], plasma VLCFA levels have never been related to X-ALD phenotypes in men and women [4].”
BackgroundInduction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics
Genin, E. C., Gondcaille, C., Trompier, D., & Savary, S. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.04.006 · Cited by 37
“ABCD4has never beendemonstrated to compensate forABCD1deficiency when overexpressed but its level of expression appears to be correlated with the severity of the X-ALD phenotypes [40].”
Wang, X.-M., Yik, W. Y., Zhang, P., Lu, W., Dranchak, P. K., Shibata, D., Steinberg, S. J., & Hacia, J. G. (2012) · Stem Cell Research & Therapy · doi:10.1186/scrt130 · Cited by 33
“It has been hypothesized to be related to the accumulation of saturated very long chain fatty acids (sVLCFAs) in specific central nervous system (CNS) cell types (for example, oligodendrocytes and microglial cells) and/or lipid classes (for example, ganglioside, phosphatidylcholine and cholesterol ester fractions) [9-…”
BackgroundMyelin lesions associated with lysosomal and peroxisomal disorders
Faust, P. L., Kaye, E. M., & Powers, J. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.127 · Cited by 33
Zhou, J., Terluk, M. R., Orchard, P. J., Cloyd, J. C., & Kartha, R. V. (2021) · Biomedicines · doi:10.3390/biomedicines9121826 · Cited by 38
“Furthermore, increased concentrations of VLCFAs in the white matter correlate with the severity of ALD phenotypes [28].”
BackgroundMolecular Biomarkers for Adrenoleukodystrophy: An Unmet Need
Honey, M. I. J., Jaspers, Y. R. J., Engelen, M., Kemp, S., & Huffnagel, I. C. (2021) · Cells · doi:10.3390/cells10123427 · Cited by 31
“Whether C26:0-lysoPC levels in the brain correlate with phenotype, as has been demonstrated for VLCFA levels [36], has not yet been investigated.”
Backgroundvan Engen, C. E., Ofman, R., Dijkstra, I. M. E., van Goethem, T. J., Verheij, E., Varin, J., Vidaud, M., Wanders, R. J. A., Aubourg, P., Kemp, S., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.006 · Cited by 26
Self-citationDeciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy
Palakuzhiyil, S. V., Christopher, R., & Chandra, S. R. (2020) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v11.i3.99 · Cited by 24
Singh, J., Khan, M., Pujol, A., Baarine, M., & Singh, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070712 · Cited by 24
Singh, J., Olle, B., Suhail, H., Felicella, M. M., & Giri, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13562 · Cited by 24
“Since VLCFA levels correlate with disease severity and inflammatory response in X-ALD in vivo and in in vitro models (Asheuer et al. 2005; Singh et al. 2009; Jang et al. 2011), lowering VLCFA levels may contribute to the overall success of a therapeutic approach in X-ALD.”
BackgroundSingh, J., Khan, M., & Singh, I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.01.004 · Cited by 21
(2006) · Springer eBooks · doi:10.1007/3-540-29623-9_9160 · Cited by 21
Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1
Boyd, M. J., Collier, P. N., Clark, M. P., Deng, H., Kesavan, S., Ronkin, S. M., Waal, N. D., Wang, J., Cao, J., Li, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00948 · Cited by 20
Verheijden, S., Beckers, L., Munter, S. D., Veldhoven, P. P. V., & Baes, M. I. (2013) · Biochimie · doi:10.1016/j.biochi.2013.08.009 · Cited by 19
“men, VLCFA levels are linked to disease severity as X-ALD patients with inflammatory demyelination (cALD) accumulate more C26:0 in normal appearing whitematter compared to patients with the noninflammatory form (AMN) [68].”
BackgroundUnmasking adrenoleukodystrophy in a cohort of cerebellar ataxia
Chen, Y., Lee, Y., Tsai, Y., Guo, Y., Hsiao, C.-T., Tsai, P., Huang, J., Liao, Y., & Soong, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177296 · Cited by 18
Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1
Come, J. H., Senter, T. J., Clark, M. P., Court, J. J., Gale-Day, Z. J., Gu, W., Krueger, E. B., Liang, J., Morris, M., Nanthakumar, S. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00944 · Cited by 17
Trompier, D., & Savary, S. (2013) · Colloquium Series on The Genetic Basis of Human Disease · doi:10.4199/c00075ed1v01y201303gbd004 · Cited by 18
Turk, B. R., Theda, C., Fatemi, A. S., & Moser, A. B. (2019) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2019.11.002 · Cited by 19
Self-citationEvolution of adrenoleukodystrophy model systems
Ferrer, R. M., Heine, V. M., Kemp, S., & Engelen, M. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12357 · Cited by 14
“C26:0 levels in normal-appearing white matter and the clinical phenotype.(69) The brain microvascular endothelial cells (BMECs) are a major cellular component of the brain-blood barrier (BBB) responsible for its selective permeability.”
BackgroundAHMED, M. A., Kartha, R. V., Brundage, R. C., Cloyd, J. C., Basu, C., Carlin, B. P., Jones, R. O., Moser, A. B., Fatemi, A. S., & Raymond, G. V. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12897 · Cited by 15
Self-citationFraisl, P., Tanaka, H., Forss‐Petter, S., Lassmann, H., Nishimune, Y., & Berger, J. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.04.013 · Cited by 15
Song, S., Kato, C., Adachi, E., Moriya‐Sato, A., Ogashiwa, M., Umeda, R., & Hashimoto, N. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21456 · Cited by 15
“In accordance with these data, BG1 transcripts (5 lipidosin mRNA) were decreased by only 1.4-fold in the white matter from AMN patients (Asheuer et al., 2005).”
BackgroundMethodInfluentialIs subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible
Cappa (2011) · PubMed · doi:10.3275/7570 · Cited by 14
Benedetto, R. D., Denti, M. A., Salvati, S., Sanchez, M., Attorri, L., David, G., & Biase, A. D. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.11.007 · Cited by 14
“analyzed the expression of ABCD genes in the normal white matter of ALD patients with different phenotypes, and found that the expression of ABCD4, but not of ABCD2 and ABCD3, tended to be correlated with the severity of the disease (Asheuer et al., 2005).”
Chu, S., Ye, J., Zhang, H., Han, L.-S., Qiu, W., Gao, X., & Gu, X. (2015) · World Journal of Pediatrics · doi:10.1007/s12519-015-0044-0 · Cited by 12
Pathophysiology of X-Linked Adrenoleukodystrophy: Updates on Molecular Mechanisms
Parasar, P., Kaur, N., & Singh, J. (2024) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280151 · Cited by 12
“ABCD2-gene does not contribute to susceptibility for cerebral demyelination owing to its similar concentrations in unaffected brain white matter in different X-ALD phenotypes [64].”
BackgroundGueugnon, F., Gondcaille, C., Leclercq, S., Bellenger, J., Bellenger, S., Narce, M., Pineau, T., Bonnetain, F., & Savary, S. (2007) · Biochimie · doi:10.1016/j.biochi.2007.06.013 · Cited by 14
Mehrpour, M., Gohari, F., Zaki‐Dizaji, M., Ahani, A., Malicdan, M. C. V., & Behnam, B. (2016) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000222 · Cited by 12
“Nevertheless, it would seem that this region may be a potential hotspot [1,20-23].”
BackgroundBasu, C., AHMED, M. A., Kartha, R. V., Brundage, R. C., Raymond, G. V., Cloyd, J. C., & Carlin, B. P. (2016) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2016.1226326 · Cited by 11
“However, little has been done to establish its clinical efficacy or indications for its use (Asheuer et al., 2005).”
BackgroundRevisiting the Pathogenesis of X-Linked Adrenoleukodystrophy
Bougnères, P., & Le Stunff, C. (2025) · Genes · doi:10.3390/genes16050590 · Cited by 11
Campopiano, R., Femiano, C., Chiaravalloti, M. A., Ferese, R., Centonze, D., Buttari, F., Zampatti, S., Fanelli, M., Amatori, S., D'Alessio, C., et al. (2021) · Genes · doi:10.3390/genes12050775 · Cited by 9
Monternier, P., Parasar, P., Theurey, P., Dagorn, P. G., Kaur, N., Nagaraja, T. N., Fouqueray, P., Bolze, S., Moller, D. E., Singh, J., et al. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001208 · Cited by 9
“Even though there is no clear association between disease severity and the degree of VLCFA accumulation in plasma (and fibroblasts from ALD patients), evidence suggests that VLCFA accumulation in normalappearing white matter may correlate with clinical status (Asheuer et al., 2005).”
BackgroundMorita, M., Kawamichi, M., Shimura, Y., Kawaguchi, K., Watanabe, S., & Imanaka, T. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9701-1 · Cited by 9
“1983), which is the most likely culprit behind both the initiation and progression of X-ALD (Asheuer et al. 2005).”
BackgroundJain, C. K., Maurya, S., & Tripathi, P. K. (2025) · Brain and Development · doi:10.1016/j.braindev.2025.104476 · Cited by 8
Hung, K., Wang, J.-S., Keng, W. T., Chen, H.-J., Liang, J., Ngu, L. H., & Lu, J. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.04.021 · Cited by 5
Šutovský, S., Kolníková, M., Petrovič, R., Kollár, B., Šiarnik, P., Chandoga, J., Fischerová, M., & Turčáni, P. (2014) · PubMed · Cited by 4
X-linked adrenoleukodystrophy presenting as Addison’s disease: Figure 1
Morell, B. K., Teichler, J., Budak, K., Vollenweider, J., & Pavlicek, V. (2010) · BMJ Case Reports · doi:10.1136/bcr.11.2009.2419 · Cited by 4
Chapleau, A., Perrier, S., Durcan, T. M., & Bernard, G. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00533-0 · Cited by 4
Choi, J., Kim, H. S., Oh, E. H., Lee, J., & Cheon, C. K. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.999419 · Cited by 3
“This variant has been previously reported in patients with X-ALD, and classified as pathogenic according to the ACMG criteria, but no functional evidence for this variation was found in the ClinVar database (16, 17).”
BackgroundLeukodystrophies and Lysosomal Storage Disorders
Escolar, M. L., & Aldenhoven, M. (2013) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4614-8357-1_4 · Cited by 3
Zhang, L., Yu, Y. F., Liu, T., Li, C., Tan, L., & Wen, S. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03499-x · Cited by 2
Basu, C., & Carlin, B. P. (2020) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315180212-13 · Cited by 3
Decreased Expression in Gastric Cancer and Its Clinical Significance Using VIKOR Method
Ranjani, T. S., & Ramadevi, C. (2023) · doi:10.46632/abfs/2/1/2 · Cited by 1
Molecular Genetics of X‐linked Adrenoleukodystrophy
Kemp, S. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0024277
Ranea‐Robles, P. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Matiytsiv, N. P., & Chernyk, Y. I. (2020) · Cytology and Genetics · doi:10.3103/s0095452720030081
Nyhan, W., Hoffmann, G. F., Barshop, B. A., & Al-Aqeel, A. (2011) · CRC Press eBooks · doi:10.1201/b15310-70
Nyhan, W., Hoffmann, G. F., Barshop, B. A., & Al-Aqeel, A. (2011) · CRC Press eBooks · doi:10.1201/b13564-70 · Cited by 1
An AAV-Based Therapy Approach for Neurological Phenotypes of X-Linked Adrenoleukodystrophy
Gornostal, E. A., Alsalloum, A., Degtyarev, E., Kuznetsova, E., Levashova, A., Mishina, D., Mingaleva, N., Mazloum, A., Bogdanov, V. P., Krupinova, J. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311645
“The iPSC modelling data are in agreement with clinical observations, demonstrating a correlation between the concentration of C26:0 in intact white matter and the severity of the clinical phenotype in X-ALD patients [185].”
Zhang, F.-Q., Zhang, Z., Wang, D., Yang, Y., & Li, X. (2026) · Clinical Case Reports · doi:10.1002/ccr3.71937
The complex lipidome as a driver of tissue-specific pathology in adrenoleukodystrophy
Kemp, S., Engelen, M., & Jaspers, Y. R. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00975-9 · Cited by 1
“Additionally, lower levels of the monounsaturated fatty acids C22:1 and C24:1 were found in patients with cerebral ALD [116].”
Chapter 17 X-Linked Spastic Paraplegia
Garbern, J. Y. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70091-7
Epigenetic Changes Associated With a Phenotypic Transition in Namibian Cheetahs
Vullioud, C., Geweiler, D., Melzheimer, J., Heinrich, S. K., Fickel, J., Wachter, B., & Weyrich, A. (2026) · Molecular Ecology · doi:10.1111/mec.70527
“ABCD4, an ATP-binding transporter involved in cobalamin metabolism, may also be relevant, as homologous pathways have been associated with hyperactivity and aggression in humans (Asheuer et al. 2005).”
BindingDB (2023) · UC San Diego · doi:10.7270/q2ff3x7k
BindingDB Entry 50016617: Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1.
BindingDB (2023) · UC San Diego · doi:10.7270/q22r3wpp
Zhou, J. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
Metadata
- Authors
- Asheuer, M., Bieche, I., Laurendeau, I., Moser, A., Hainque, B., Vidaud, M., & Aubourg, P.
- Affiliations
- Inserm (FR)
- Corresponding author
- Asheuer, Muriel
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03-30
- Volume
- 14
- Issue
- 10
- Pages
- 1293-1303
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2168710549
- Cited by
- 86
- References
- 65
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 5 · 2013: 7 · 2012: 3
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Association Européenne contre les Leucodystrophies
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- X-linked adrenoleukodystrophy, ABCD4, ABCD1, ABCD2, ABCD3, very long chain fatty acids, genotype-phenotype correlation, genetic modifiers, childhood cerebral adrenoleukodystrophy, adrenomyeloneuropathy, normal-appearing white matter, gene expression, disease severity
- MeSH terms
- Long-Chain-Fatty-Acid-CoA Ligase, Adrenoleukodystrophy, Brain, Cells, Cultured, Coenzyme A Ligases, Fibroblasts, Humans, Membrane Proteins, ATP-Binding Cassette Transporters
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.